Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics, Inc. (AXSM) Healthcare & Pipeline Overview

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders in the United States. The company advances a diverse pipeline of investigational medicines, including product candidates in Phase III clinical trials for major depressive disorder, Alzheimer's disease agitation, narcolepsy, and fibromyalgia, addressing areas with significant unmet medical needs.

What Is the Investment Thesis for AXSM?

Axsome Therapeutics, Inc. (AXSM) presents an investment profile centered on its advanced and diversified pipeline targeting significant central nervous system (CNS) disorders. With a market capitalization of $12.39B, the company is valued based on the future potential of its investigational assets. A key value driver is the progression of multiple product candidates, such as AXS-05 for major depressive disorder and Alzheimer's disease agitation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, all of which are in or have completed late-stage clinical trials. Successful regulatory approvals and subsequent commercialization of even a few of these candidates could significantly transform the company's financial trajectory, moving from its current profit margin of -26.6% to profitability. The high gross margin of 92.6% suggests strong profitability potential once products are commercialized and scale is achieved. Growth catalysts include upcoming data readouts from ongoing Phase III trials, potential New Drug Application (NDA) submissions, and regulatory approvals. The company's focus on CNS disorders, a market with substantial unmet needs, provides a large addressable patient population. However, risks include the inherent uncertainties of clinical trial success, regulatory hurdles, intense competition in therapeutic areas, and the significant capital required for R&D and commercial launch. The company's beta of 0.58 indicates relatively lower volatility compared to the broader market, which might appeal to certain investor profiles.

Based on FMP financials and quantitative analysis

AXSM Key Highlights

• **Market Capitalization:** Axsome Therapeutics commands a market capitalization of $12.39B, reflecting investor valuation of its late-stage biopharmaceutical pipeline and future commercial potential in the CNS therapeutic area.
• **Profit Margin:** The company reports a profit margin of -26.6%, which is typical for a biopharmaceutical company heavily invested in research and development prior to widespread commercialization of its lead assets.
• **Gross Margin Potential:** Axsome exhibits a robust gross margin of 92.6%, indicating strong potential profitability for its products once they achieve regulatory approval and commercial scale, demonstrating efficient cost structures for future sales.
• **Beta:** With a beta of 0.58, Axsome Therapeutics demonstrates lower volatility compared to the broader market, suggesting a more stable price movement relative to market fluctuations.
• **Extensive CNS Pipeline:** The company maintains a diverse pipeline of novel therapies for central nervous system disorders, with multiple candidates like AXS-05, AXS-07, AXS-12, and AXS-14 in or having completed Phase III clinical trials, addressing significant unmet medical needs.

Who Are AXSM's Competitors?

AXSM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AXSM's Key Strengths?

• Diverse and late-stage pipeline addressing significant unmet needs in CNS disorders.
• High gross margin potential (92.6%) for future commercialized products.
• Strategic research collaboration with Duke University for AXS-05.
• Focus on novel mechanisms of action for potentially differentiated therapies.

What Are AXSM's Weaknesses?

• Currently operating at a negative profit margin (-26.6%), typical for a development-stage biotech.
• Reliance on successful clinical trial outcomes and regulatory approvals for future revenue generation.
• Significant capital expenditure required for R&D and potential commercialization.
• Limited commercialized products currently generating substantial revenue.

What Could Drive AXSM Stock Higher?

• **Upcoming:** Potential New Drug Application (NDA) submissions for AXS-07 for acute migraine treatment, following the completion of two Phase III trials.
• **Upcoming:** Data readouts from the ongoing Phase III clinical trial for AXS-05 in Alzheimer's disease agitation, which could support future regulatory filings.
• **Upcoming:** Progression and potential positive data from the Phase III trial of AXS-12 for narcolepsy, moving closer to a potential regulatory submission.
• **Upcoming:** Further clinical development milestones for AXS-14 in fibromyalgia, including potential completion of its Phase III trial.
• **Ongoing:** Continued enrollment and progress in the Phase III clinical trial for AXS-05 in Alzheimer's disease agitation, a significant market opportunity.

What Are the Key Risks for AXSM?

• Rich valuation — a P/E of 39.8 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• **Potential:** Failure of ongoing Phase III clinical trials (e.g., AXS-05 for Alzheimer's agitation, AXS-12 for narcolepsy, AXS-14 for fibromyalgia) to meet primary endpoints, leading to delays or discontinuation of development.
• **Potential:** Regulatory hurdles and delays in obtaining New Drug Application (NDA) approvals from the FDA for pipeline candidates, even after successful clinical trials.
• **Ongoing:** Intense competition in the CNS therapeutic market from established pharmaceutical companies and other biotechnology firms developing similar or alternative treatments.
• **Ongoing:** Significant capital requirements for continued research and development, as well as for potential commercialization efforts, which could necessitate future financing.
• **Potential:** Challenges in intellectual property protection, including patent expirations or successful challenges by competitors, which could erode market exclusivity for approved products.

What Are the Growth Opportunities for AXSM?

• **Commercialization of AXS-05 for Major Depressive Disorder (MDD) and Resistant Depression:** AXS-05 is a key asset for Axsome, targeting MDD and resistant depression disorders, conditions affecting millions globally with significant unmet needs for effective, rapid-acting treatments. The global antidepressant market is substantial, with estimates often exceeding tens of billions of dollars annually. Successful regulatory approval and subsequent market launch would provide Axsome with a significant revenue stream, leveraging its novel mechanism of action to capture market share from existing therapies. The ongoing need for improved efficacy and tolerability in depression treatments positions AXS-05 for strong adoption, potentially within the next 1-3 years following approval.
• **Advancement and Approval of AXS-05 for Alzheimer's Disease Agitation:** The progression of AXS-05 into Phase III clinical trials for Alzheimer's disease agitation represents a substantial growth opportunity. Agitation is a common and distressing symptom in Alzheimer's patients, with limited approved treatment options. The market for Alzheimer's related symptoms is projected to grow significantly as the global population ages, potentially reaching billions of dollars. Successful development and approval in this indication would address a critical unmet need, offering a new therapeutic avenue for a large and growing patient population, potentially within a 3-5 year timeline for market entry.
• **Launch of AXS-07 for Acute Migraine Treatment:** AXS-07 has completed two Phase III trials for the acute treatment of migraine, a highly prevalent neurological condition affecting over a billion people worldwide. The global migraine therapeutics market is a multi-billion dollar industry, driven by the need for fast-acting, effective, and well-tolerated treatments. AXS-07's novel, oral, rapidly absorbed, and multi-mechanistic profile positions it as a potentially differentiated option in a competitive market. Successful regulatory approval and commercialization could allow Axsome to capture a meaningful share of this large market, with potential market entry within the next 1-2 years.
• **Commercialization of AXS-12 for Narcolepsy:** AXS-12, a selective and potent norepinephrine reuptake inhibitor, is in a Phase III trial for narcolepsy, a chronic neurological disorder characterized by excessive daytime sleepiness. While narcolepsy is considered an orphan disease, the market for narcolepsy treatments is a specialized and growing segment, valued at several billion dollars globally. The unmet need for improved treatment options, particularly those addressing specific symptoms with better tolerability profiles, provides a clear market opportunity for AXS-12. Successful development and approval would allow Axsome to enter a high-value, specialized market, potentially within a 2-4 year timeframe.
• **Development and Approval of AXS-14 for Fibromyalgia:** AXS-14 is an investigational medicine in Phase III for the treatment of fibromyalgia, a chronic widespread pain condition affecting millions of individuals. The global fibromyalgia treatment market is substantial, driven by the chronic nature of the disease and the need for more effective and tolerable long-term management strategies. AXS-14's novel oral formulation could offer a differentiated therapeutic option, addressing a significant patient population seeking relief from chronic pain and fatigue. Successful clinical development and regulatory approval would open access to a multi-billion dollar market, with potential commercialization within a 3-5 year outlook.

What Opportunities Does AXSM Have?

• Potential market entry and revenue generation from multiple Phase III candidates (AXS-05, AXS-07, AXS-12, AXS-14).
• Expansion into large and growing markets for MDD, Alzheimer's agitation, migraine, narcolepsy, and fibromyalgia.
• Leveraging existing pipeline assets for additional indications (e.g., AXS-05 for smoking cessation).
• Strategic partnerships or licensing agreements to accelerate global reach or expand commercial capabilities.

What Threats Does AXSM Face?

• Clinical trial failures or unexpected safety concerns delaying or halting drug development.
• Intense competition from established pharmaceutical companies and other biotech firms.
• Regulatory setbacks, including delays in approval or unfavorable labeling decisions.
• Patent challenges or the emergence of biosimilars/generics impacting market exclusivity.
• Pricing pressures and reimbursement challenges from healthcare payers.

What Are AXSM's Competitive Advantages?

• **Differentiated Pipeline:** A robust pipeline of novel investigational medicines targeting multiple CNS disorders, each with potentially unique mechanisms of action.
• **Intellectual Property:** Protection through patents and other intellectual property rights for its drug candidates and formulations, providing market exclusivity upon approval.
• **Clinical Expertise:** Specialized R&D capabilities and expertise in navigating complex clinical trials for CNS indications, a challenging therapeutic area.
• **Regulatory Experience:** Accumulating experience in managing the regulatory approval processes for novel CNS therapies.

What Does AXSM Do?

Axsome Therapeutics, Inc., established in 2012 and headquartered in New York City, New York, operates as a biopharmaceutical company dedicated to the development and potential commercialization of innovative therapies for central nervous system (CNS) disorders within the United States. From its inception, Axsome has strategically focused on addressing conditions that represent substantial unmet medical needs, aiming to improve the lives of patients suffering from debilitating neurological and psychiatric conditions. The company's evolution has been marked by a robust commitment to research and development, building a comprehensive pipeline of differentiated product candidates. Axsome's core strategy revolves around leveraging its scientific expertise to identify and advance novel mechanisms of action for CNS indications. Its product portfolio is anchored by several key investigational medicines. AXS-05 is a prominent asset, currently being developed for the treatment of major depressive disorder (MDD) and resistant depression disorders, and is also in a Phase III clinical trial for Alzheimer's disease agitation. Furthermore, AXS-05 has completed a Phase II clinical trial for smoking cessation, highlighting its multi-faceted potential. Another significant candidate is AXS-07, an oral, rapidly absorbed, multi-mechanistic investigational medicine that has successfully completed two Phase III trials for the acute treatment of migraine, a widespread and often debilitating condition. The company's pipeline further includes AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is progressing through a Phase III trial for the treatment of narcolepsy, a chronic neurological condition characterized by overwhelming daytime sleepiness. Additionally, AXS-14, a novel oral investigational medicine, is in a Phase III trial targeting fibromyalgia, a chronic disorder associated with widespread pain and fatigue. Axsome Therapeutics maintains a research collaboration agreement with Duke University, specifically for the evaluation of AXS-05 in smoking cessation, underscoring its commitment to external partnerships to broaden its research scope. With a workforce of 712 employees, Axsome is positioned to continue its efforts in bringing these specialized therapies through clinical development and, ultimately, to market.

What Products and Services Does AXSM Offer?

• Develops novel therapies for central nervous system (CNS) disorders.
• Focuses on conditions like major depressive disorder, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia.
• Conducts extensive research and development, including preclinical and clinical trials.
• Advances a pipeline of investigational medicines, with several candidates in late-stage (Phase III) clinical trials.
• Collaborates with academic institutions, such as Duke University, for specific research initiatives.
• Aims to bring new, differentiated treatment options to patients in the United States.
• Specializes in biopharmaceutical innovation for complex neurological and psychiatric conditions.

How Does AXSM Make Money?

• **Research and Development:** Invests heavily in the discovery and clinical development of novel drug candidates for CNS disorders.
• **Regulatory Approval:** Seeks regulatory approvals (e.g., FDA approval in the US) for its investigational medicines based on clinical trial data.
• **Commercialization:** Plans to commercialize approved therapies, generating revenue through product sales.
• **Partnerships:** Engages in strategic research collaborations to expand its scientific capabilities and potential indications.

What Industry Does AXSM Operate In?

Axsome Therapeutics operates within the highly specialized and competitive Biotechnology industry, a sub-sector of Healthcare, focusing specifically on central nervous system (CNS) disorders. This industry is characterized by extensive research and development cycles, significant capital investment, and high regulatory hurdles. The CNS therapeutic area represents a substantial market with persistent unmet medical needs across conditions such as depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Global CNS therapeutics market is projected to grow due to aging populations, increased prevalence of neurological disorders, and advancements in understanding disease mechanisms. Axsome positions itself by developing novel, differentiated mechanisms of action for these complex conditions, aiming to offer improved treatment options. The competitive landscape includes both large pharmaceutical companies with established CNS portfolios and numerous smaller biotech firms vying for market share. Axsome's strategy of advancing multiple late-stage candidates simultaneously across diverse CNS indications allows it to potentially capture significant portions of these specialized markets, differentiating it from companies with narrower pipelines.

Who Are AXSM's Key Customers?

• **Patients:** Individuals suffering from central nervous system disorders such as depression, migraine, narcolepsy, Alzheimer's disease agitation, and fibromyalgia.
• **Healthcare Providers:** Physicians, neurologists, psychiatrists, and other medical professionals who prescribe treatments for CNS conditions.
• **Payers:** Insurance companies and government healthcare programs that cover the cost of prescription medications.

Axsome Therapeutics, Inc. (AXSM) Valuation Context

Valued at $12.39B, AXSM is classified as a large-cap stock. Relative to its peer group, AXSM's quantitative score of 31/100 is below the peer average of 49/100.

AXSM Revenue & Earnings Trend

In Q1 2026, AXSM generated $191.2M in top-line revenue, marking a sequential decrease of 2.4%. The company recorded a net loss of $64.5M, with diluted EPS of $-1.26. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, AXSM averaged $-0.93 in diluted EPS.

Company Profile

Axsome Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Herriot Tabuteau. AXSM has traded publicly since 2015.

P/E 39.8Key Financial Metrics

Return on assets is -26.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.5%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Axsome Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 9.20 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Axsome Therapeutics, Inc. revenue of about $983.6M for fiscal 2026, with EPS near $-2.14. The estimate reflects 16 contributing analysts.

AXSM Financials

AXSM Latest News

AXSM Analyst Consensus

AXSM MoonshotScore

Latest Axsome Therapeutics, Inc. Analysis

Axsome Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources